Skip to main content
Premium Trial:

Request an Annual Quote

Kathleen LaPorte

Precipio has appointed Kathleen LaPorte to its board as an independent member. She will replace Michael Allen Luther, who first served on the board of Transgenomic starting in 2014 and remained on it after that firm merged with Precipio.  

LaPorte was a general partner with Sprout Group from 1993 to 2004 and was a founder of New Leaf Venture Partners. She is also a cofounder of Health Tech Capital and was CEO of immuno-oncology diagnostic company Nodality. 

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.